This is the running cash receipts graphed as well. You can see that cash lumpiness in every preceeding 3Q (blue columns). Again, I am not defending the company, I expected it to be less pronounced as US and EU business grows (Australia probably third only to France and Italy in its summer business shut down) but guys you have to look at these figures in the context of past quarterly patterns of sales - sure the cash sales receipts a QoQ -28% decline, but YoY quarterly comparison a +143% increase (in part because 3Q FY23 was so low admittedly):
Revenues on a yearly basis are growing quite nicely - not quick enough for my liking in case I get accused of pump.
- Forums
- ASX - By Stock
- OCC
- Ann: Quarterly Activity Report & Appendix 4C
OCC
orthocell limited
Add to My Watchlist
8.47%
!
$1.35

Ann: Quarterly Activity Report & Appendix 4C, page-7
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.35 |
Change
0.105(8.47%) |
Mkt cap ! $327.2M |
Open | High | Low | Value | Volume |
$1.25 | $1.37 | $1.25 | $2.832M | 2.156M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 257 | $1.35 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.36 | 5000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 257 | 1.345 |
1 | 2933 | 1.340 |
2 | 4256 | 1.330 |
1 | 9000 | 1.325 |
1 | 800 | 1.320 |
Price($) | Vol. | No. |
---|---|---|
1.360 | 5000 | 1 |
1.370 | 45690 | 2 |
1.375 | 2000 | 1 |
1.380 | 28365 | 3 |
1.390 | 5000 | 1 |
Last trade - 16.18pm 04/07/2025 (20 minute delay) ? |
Featured News
OCC (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online